Featured
FDA Reviews Two Novel ADHD Drug Candidates in Late-Stage Development
Clinic Moves Sep 21, 2026
Drug Approvals Sep 19, 2026
Vaccine News Sep 18, 2026
FDA reviews two novel ADHD drug candidates in late-stage development, offering new approaches to treatment.
Zorevunersen dravet patients showed adaptive gains over two years, surpassing standard antiseizure therapy in a...
Discover the latest stroke rehabilitation guidelines from American Heart Association for improved recovery outcomes with...
Read our latest Drug Approvals articles.
Doctors reject federal vaccine changes lacking scientific backing as top medical groups like AAP and...
Vonoprazan significantly reduces nighttime reflux symptoms in patients with NERD, offering a promising new treatment...
GammaTile slows brain tumor regrowth in glioblastoma patients with promising results from the GESTALT trial...
FDA reviews two novel ADHD drug candidates in late-stage development, offering new approaches to treatment.
FDA reviews two novel ADHD drug candidates in late-stage development, offering new approaches to treatment.
Doctors reject federal vaccine changes lacking scientific backing as top medical groups like AAP and ACOG defend evidence-based immunization schedules.
Effective strategies for managing challenging patient relationships, focusing on cases where patients reject care or question competence.
The FIB-4 index celebrates 20 years as a non‑invasive tool for spotting advanced liver fibrosis in MASLD, MASH, hepatitis C...
New ATA guidelines for thyroid disease in pregnancy and preconception provide expert updates on testing, hypothyroidism, and iodine intake for...
Noninvasive tests now replace risky liver biopsies for diagnosing metabolic dysfunction-associated steatohepatitis (MASH) and MASLD, offering safer, cost-effect
Stubborn eczema may signal hidden conditions, so the American Academy of Dermatology now urges doctors to run new tests before...
The new American Association of Neurology and American Headache Society guideline outlines migraine preventive pharmacologic treatment for adults,.
Early kidney disease diagnosis rates remain stagnant despite increased screening, highlighting challenges in healthcare detection.
Vonoprazan significantly reduces nighttime reflux symptoms in patients with NERD, offering a promising new treatment option for better sleep.